Indonesia reaches deal on H5N1 vaccine access
The Indonesian government has authorized the sharing of 12 avian influenza virus samples with the World Health Organization, according to a report on Yahoo! news. The move confirms that a deal has been concluded with the global agency to guarantee that intellectual property rights to any drugs derived from the samples are shared with the Indonesian government.
Siti Fadilah Supari, Indonesia's Health Minister, said that the virus samples were delivered from Jakarta to the US Centers for Disease Control and Prevention (CDC) in Atlanta. Ms Supari added that the US facility was authorized to conduct evaluations of the virus' risk to humans but not to use it for potential vaccine research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze